PE20201256A1 - Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas - Google Patents
Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianasInfo
- Publication number
- PE20201256A1 PE20201256A1 PE2020000692A PE2020000692A PE20201256A1 PE 20201256 A1 PE20201256 A1 PE 20201256A1 PE 2020000692 A PE2020000692 A PE 2020000692A PE 2020000692 A PE2020000692 A PE 2020000692A PE 20201256 A1 PE20201256 A1 PE 20201256A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hydrogen
- compounds
- treatment
- bacterial infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invencion se refiere a un compuesto de formula (I), o una sal farmaceuticamente aceptable, en donde: T es CH o N, siempre que no mas de dos T, U y V sean N; U y V son CH o N; W es un enlace u O; Q es N o CR3; X es O o CH2; Y es O, S, CH2 o NR8, siempre que cuando Y es O, NR8 o S, X no es O; Z es O, S, CH2 o NH, siempre que cuando Z es O, S o NH, X no es O; A es -C(=NH)-NH, cicloalquilo C3-C7, entre otros; L esta ausente o es R4, NHR4, entre otros; M es R5, NHR5, entre otros; R1 es hidrogeno, alquilo C1-C8, entre otros; R2 es hidrogeno, alquilo C1-C8, cicloalquilo C3-C7, entre otros; R3 es hidrogeno, alquilo C1-C4, entre otros; R8 es hidrogeno, alquilo C1-C4 o cicloalquilo C3-C7; Rb es hidrogeno, alquilo C1-C6, entre otros; Rj es hidrogeno, alquilo C1-C3, entre otros; s y t son 0 a 3. Son compuestos especificos, los compuestos de formulas i) a iv), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son analogos monobactamicos novedosos, los cuales son altamente potentes y eficaces contra un amplio rango de bacterias gran-negativas, siendo utiles en el tratamiento de infecciones bacterianas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762566779P | 2017-10-02 | 2017-10-02 | |
PCT/US2018/053039 WO2019070492A1 (en) | 2017-10-02 | 2018-09-27 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20201256A1 true PE20201256A1 (es) | 2020-11-16 |
Family
ID=65994576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000692A PE20201256A1 (es) | 2017-10-02 | 2018-09-27 | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas |
Country Status (25)
Country | Link |
---|---|
US (1) | US11433055B2 (es) |
EP (1) | EP3691639B1 (es) |
JP (1) | JP7252948B2 (es) |
KR (1) | KR102425959B1 (es) |
CN (1) | CN111201021A (es) |
AU (1) | AU2018345523B2 (es) |
BR (1) | BR112020006381A8 (es) |
CA (1) | CA3076022C (es) |
CL (1) | CL2020000860A1 (es) |
CO (1) | CO2020004087A2 (es) |
CR (1) | CR20200148A (es) |
DO (1) | DOP2020000058A (es) |
EA (1) | EA202090604A1 (es) |
GE (1) | GEP20227406B (es) |
IL (1) | IL273306B (es) |
JO (1) | JOP20200130A1 (es) |
MA (1) | MA50629A (es) |
MX (1) | MX2020003581A (es) |
NI (1) | NI202000023A (es) |
PE (1) | PE20201256A1 (es) |
PH (1) | PH12020550107A1 (es) |
SG (1) | SG11202002575UA (es) |
UA (1) | UA126000C2 (es) |
WO (1) | WO2019070492A1 (es) |
ZA (1) | ZA202001721B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110156697B (zh) * | 2019-05-30 | 2022-05-06 | 常州沃腾化工科技有限公司 | 一种1,2-二甲基-1,4,5,6-四氢嘧啶的合成方法 |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
MX2023000056A (es) | 2020-07-02 | 2023-04-12 | Incyte Corp | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US20240051931A1 (en) * | 2020-12-03 | 2024-02-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hdac inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
TWI829432B (zh) * | 2021-11-18 | 2024-01-11 | 美商默沙東有限責任公司 | 用於治療細菌感染之唍脒單環內醯胺(monobactam)化合物 |
WO2024019916A2 (en) * | 2022-07-18 | 2024-01-25 | Merck Sharp & Dohme Llc | Chromane amidine monobactam compounds for the treatment of bacterial infections |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
US5250691A (en) | 1991-09-09 | 1993-10-05 | E. R. Squibb & Sons, Inc. | Heteroaryl derivatives of monocyclic beta-lactam antibiotics |
KR101403164B1 (ko) | 2005-12-07 | 2014-06-03 | 바실리어 파마슈티카 아게 | 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합 |
EP1938822A1 (en) * | 2006-12-21 | 2008-07-02 | Novartis AG | Combination therapy for the treatment of airways disease |
LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
SG190007A1 (en) | 2010-11-29 | 2013-06-28 | Pfizer | Monobactams |
UY34585A (es) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
PT2857039T (pt) | 2012-05-31 | 2020-01-07 | Teijin Pharma Ltd | Agente terapêutico ou profilático para demência |
US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
PE20161371A1 (es) | 2014-03-24 | 2016-12-21 | Novartis Ag | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas |
TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
CA3191010A1 (en) * | 2014-10-31 | 2016-05-06 | AbbVie Global Enterprises Ltd. | Substituted chromanes and method of use |
FR3031423B1 (fr) * | 2015-01-06 | 2018-11-30 | Centre National De La Recherche Scientifique | Procede et dispositif de conversion de courant et vehicule comportant un tel dispositif |
US20180339983A1 (en) * | 2015-12-15 | 2018-11-29 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
US10407421B2 (en) * | 2016-03-07 | 2019-09-10 | Merck Sharp & Dohme Corp | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
-
2018
- 2018-09-27 GE GEAP201815303A patent/GEP20227406B/en unknown
- 2018-09-27 BR BR112020006381A patent/BR112020006381A8/pt unknown
- 2018-09-27 WO PCT/US2018/053039 patent/WO2019070492A1/en active Application Filing
- 2018-09-27 EA EA202090604A patent/EA202090604A1/ru unknown
- 2018-09-27 CA CA3076022A patent/CA3076022C/en active Active
- 2018-09-27 MA MA050629A patent/MA50629A/fr unknown
- 2018-09-27 SG SG11202002575UA patent/SG11202002575UA/en unknown
- 2018-09-27 AU AU2018345523A patent/AU2018345523B2/en active Active
- 2018-09-27 CN CN201880064269.2A patent/CN111201021A/zh active Pending
- 2018-09-27 JP JP2020518661A patent/JP7252948B2/ja active Active
- 2018-09-27 KR KR1020207012234A patent/KR102425959B1/ko active IP Right Grant
- 2018-09-27 EP EP18864229.2A patent/EP3691639B1/en active Active
- 2018-09-27 MX MX2020003581A patent/MX2020003581A/es unknown
- 2018-09-27 US US16/651,456 patent/US11433055B2/en active Active
- 2018-09-27 JO JOP/2020/0130A patent/JOP20200130A1/ar unknown
- 2018-09-27 UA UAA202002037A patent/UA126000C2/uk unknown
- 2018-09-27 PE PE2020000692A patent/PE20201256A1/es unknown
- 2018-09-27 CR CR20200148A patent/CR20200148A/es unknown
-
2020
- 2020-03-15 IL IL273306A patent/IL273306B/en unknown
- 2020-03-16 DO DO2020000058A patent/DOP2020000058A/es unknown
- 2020-03-18 ZA ZA2020/01721A patent/ZA202001721B/en unknown
- 2020-03-20 PH PH12020550107A patent/PH12020550107A1/en unknown
- 2020-03-24 NI NI202000023A patent/NI202000023A/es unknown
- 2020-03-31 CL CL2020000860A patent/CL2020000860A1/es unknown
- 2020-03-31 CO CONC2020/0004087A patent/CO2020004087A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
PE20210140A1 (es) | Moduladores de la proteina reguladora de conductancia transmembrana de la fibrosis quistica y metodos de uso | |
PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
AR074833A1 (es) | Agentes lipopeptidicos antibacterianos para el tratamiento de infecciones con grampositivos | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR054272A1 (es) | Derivados de 3- aminopirrilidinas tri, tetra - sustituidos | |
AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
SV2010003464A (es) | Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas | |
AR076645A1 (es) | Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales. | |
PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
PE20120054A1 (es) | COMPUESTOS DERIVADOS DE 4,8-DIHIDRO-4,7-METANO-7H-PIRAZOLO[3,4-e][1,3]DIAZEPINA-6(5H)-ONA CON ACTIVIDAD ANTIBACTERIANA | |
PE20230002A1 (es) | Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano | |
PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
PE20210478A1 (es) | Compuestos heteroaromaticos como inhibidores de vanina | |
AR072880A1 (es) | Derivados nitrogenados de la pancratistatina | |
AR054888A1 (es) | Derivados de quinolina como agentes antibacterianos | |
AR062131A1 (es) | Profarmacos antimicrobianos de oxazolidinona | |
BR112013024497A2 (pt) | novo derivado de oxazolidinona e composição farmacêutica incluindo o mesmo | |
PE20201148A1 (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias |